- call +1-201-465-4211
- email sales@mrinsights.biz
A glioma is a type of tumor that originates in the brain and is also known as a primary brain tumor. There are numerous types of gliomas which are entitled based on the origin of the cell type including oligodendrogliomas, astrocytoma, ependymomas, and glioblastoma. Nearly 33 percent of all brain tumors are gliomas.
Scope of the Report:
This report studies the Glioma Diagnosis and Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Glioma Diagnosis and Treatment market by product type and applications/end industries.
Astrocytoma is the most common types of glioma diagnosed worldwide, as more than 30% of all the diagnosed cases with brain tumors are astrocytoma. These types of tumors are not curable as they spread easily through normal brain tissue. The American Brain Tumor Association has evaluated that around 7% of all the primary brain tumors represent astrocytoma.
The global Glioma Diagnosis and Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Glioma Diagnosis and Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Thermo Fisher Scientific
Emcure Pharmaceuticals
Sigma-Aldrich
Pfizer
Taj Pharmaceuticals
Novartis International
Teva Pharmaceutical
GE Healthcare
Siemens Healthcare
Philips Healthcare
Shimadzu Corporation
Toshiba Medical
Merck
Roche
Arbor Pharmaceuticals
Sun Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Diagnosis (CT, MRI)
Treatment (Surgery, Chemotherapy)
Market Segment by Applications, can be divided into
Hospitals
Clinics
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Glioma Diagnosis and Treatment Market Overview
1.1 Product Overview and Scope of Glioma Diagnosis and Treatment
1.2 Classification of Glioma Diagnosis and Treatment by Types
1.2.1 Global Glioma Diagnosis and Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Glioma Diagnosis and Treatment Revenue Market Share by Types in 2017
1.2.3 Diagnosis (CT, MRI)
1.2.4 Treatment (Surgery, Chemotherapy)
1.3 Global Glioma Diagnosis and Treatment Market by Application
1.3.1 Global Glioma Diagnosis and Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.4 Global Glioma Diagnosis and Treatment Market by Regions
1.4.1 Global Glioma Diagnosis and Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Glioma Diagnosis and Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Glioma Diagnosis and Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Glioma Diagnosis and Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Glioma Diagnosis and Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Glioma Diagnosis and Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Glioma Diagnosis and Treatment (2013-2023)
2 Manufacturers Profiles
2.1 Thermo Fisher Scientific
2.1.1 Business Overview
2.1.2 Glioma Diagnosis and Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Thermo Fisher Scientific Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 Emcure Pharmaceuticals
2.2.1 Business Overview
2.2.2 Glioma Diagnosis and Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Emcure Pharmaceuticals Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 Sigma-Aldrich
2.3.1 Business Overview
2.3.2 Glioma Diagnosis and Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Sigma-Aldrich Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Glioma Diagnosis and Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Pfizer Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.5 Taj Pharmaceuticals
2.5.1 Business Overview
2.5.2 Glioma Diagnosis and Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Taj Pharmaceuticals Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.6 Novartis International
2.6.1 Business Overview
2.6.2 Glioma Diagnosis and Treatment Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Novartis International Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.7 Teva Pharmaceutical
2.7.1 Business Overview
2.7.2 Glioma Diagnosis and Treatment Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Teva Pharmaceutical Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.8 GE Healthcare
2.8.1 Business Overview
2.8.2 Glioma Diagnosis and Treatment Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 GE Healthcare Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.9 Siemens Healthcare
2.9.1 Business Overview
2.9.2 Glioma Diagnosis and Treatment Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Siemens Healthcare Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.10 Philips Healthcare
2.10.1 Business Overview
2.10.2 Glioma Diagnosis and Treatment Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Philips Healthcare Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.11 Shimadzu Corporation
2.11.1 Business Overview
2.11.2 Glioma Diagnosis and Treatment Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Shimadzu Corporation Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.12 Toshiba Medical
2.12.1 Business Overview
2.12.2 Glioma Diagnosis and Treatment Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Toshiba Medical Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.13 Merck
2.13.1 Business Overview
2.13.2 Glioma Diagnosis and Treatment Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Merck Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.14 Roche
2.14.1 Business Overview
2.14.2 Glioma Diagnosis and Treatment Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Roche Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.15 Arbor Pharmaceuticals
2.15.1 Business Overview
2.15.2 Glioma Diagnosis and Treatment Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Arbor Pharmaceuticals Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.16 Sun Pharmaceutical
2.16.1 Business Overview
2.16.2 Glioma Diagnosis and Treatment Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Sun Pharmaceutical Glioma Diagnosis and Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Glioma Diagnosis and Treatment Market Competition, by Players
3.1 Global Glioma Diagnosis and Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Glioma Diagnosis and Treatment Players Market Share
3.2.2 Top 10 Glioma Diagnosis and Treatment Players Market Share
3.3 Market Competition Trend
4 Global Glioma Diagnosis and Treatment Market Size by Regions
4.1 Global Glioma Diagnosis and Treatment Revenue and Market Share by Regions
4.2 North America Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
5 North America Glioma Diagnosis and Treatment Revenue by Countries
5.1 North America Glioma Diagnosis and Treatment Revenue by Countries (2013-2018)
5.2 USA Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
6 Europe Glioma Diagnosis and Treatment Revenue by Countries
6.1 Europe Glioma Diagnosis and Treatment Revenue by Countries (2013-2018)
6.2 Germany Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
6.4 France Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Glioma Diagnosis and Treatment Revenue by Countries
7.1 Asia-Pacific Glioma Diagnosis and Treatment Revenue by Countries (2013-2018)
7.2 China Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
7.5 India Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
8 South America Glioma Diagnosis and Treatment Revenue by Countries
8.1 South America Glioma Diagnosis and Treatment Revenue by Countries (2013-2018)
8.2 Brazil Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Glioma Diagnosis and Treatment by Countries
9.1 Middle East and Africa Glioma Diagnosis and Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Glioma Diagnosis and Treatment Revenue and Growth Rate (2013-2018)
10 Global Glioma Diagnosis and Treatment Market Segment by Type
10.1 Global Glioma Diagnosis and Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Glioma Diagnosis and Treatment Market Forecast by Type (2018-2023)
10.3 Diagnosis (CT, MRI) Revenue Growth Rate (2013-2023)
10.4 Treatment (Surgery, Chemotherapy) Revenue Growth Rate (2013-2023)
11 Global Glioma Diagnosis and Treatment Market Segment by Application
11.1 Global Glioma Diagnosis and Treatment Revenue Market Share by Application (2013-2018)
11.2 Glioma Diagnosis and Treatment Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
12 Global Glioma Diagnosis and Treatment Market Size Forecast (2018-2023)
12.1 Global Glioma Diagnosis and Treatment Market Size Forecast (2018-2023)
12.2 Global Glioma Diagnosis and Treatment Market Forecast by Regions (2018-2023)
12.3 North America Glioma Diagnosis and Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Glioma Diagnosis and Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Glioma Diagnosis and Treatment Revenue Market Forecast (2018-2023)
12.6 South America Glioma Diagnosis and Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Glioma Diagnosis and Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Glioma Diagnosis and Treatment Picture
Table Product Specifications of Glioma Diagnosis and Treatment
Table Global Glioma Diagnosis and Treatment and Revenue (Millio
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
